{
    "clinical_study": {
        "@rank": "72421", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Evaluate the toxicity of cytarabine in patients with refractory systemic\n      lupus erythematosus.\n\n      II.  Evaluate objective disease parameters, including serum complement levels, anti-DNA\n      antibody titers, sedimentation rate, and the systemic lupus activity measure in these\n      patients."
        }, 
        "brief_title": "Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus", 
        "condition": "Lupus Erythematosus, Systemic", 
        "condition_browse": {
            "mesh_term": "Lupus Erythematosus, Systemic"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE:\n\n      Subcutaneous cytarabine is given for 5 days.  Patients are re-treated every 4 weeks for a\n      maximum of 3 courses; those who relapse prior to the second course are re-treated every 3\n      weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        Disease Characteristics\n\n          -  Clinically documented active systemic lupus erythematosus demonstrating at least 4\n             revised diagnostic criteria\n\n          -  Unresponsive to conventional therapy with nonsteroidal anti-inflammatory drugs\n             (NSAIDs), topical corticosteroids, and antimalarials\n\n          -  Intolerable side effects from corticosteroids or other immunosuppressive drugs\n             Failure on immunosuppressives not required\n\n          -  No life-threatening disease, e.g.: Lupus cerebritis Rapidly progressive\n             glomerulonephritis\n\n        Prior/Concurrent Therapy\n\n          -  No concurrent other DNA synthesis inhibitors, NSAIDs, and prednisone continued on\n             study\n\n        Patient Characteristics\n\n          -  Hematopoietic: WBC at least 2000; Platelets at least 100,000\n\n          -  Renal: Creatinine clearance at least 20 mL/min\n\n          -  Other: No major infection within 2 weeks prior to entry\n\n          -  Negative pregnancy test required of fertile women\n\n          -  Effective contraception required of fertile women. Advised for men during and for 75\n             days after therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "10", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004643", 
            "org_study_id": "199/11685", 
            "secondary_id": "UMMC-91208"
        }, 
        "intervention": {
            "intervention_name": "cytarabine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Cytarabine"
        }, 
        "keyword": [
            "arthritis & connective tissue diseases", 
            "immunologic disorders and infectious disorders", 
            "rare disease", 
            "systemic lupus erythematosus"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of Michigan", 
            "last_name": "Bruce Richardson", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "reference": {
            "PMID": "7575733", 
            "citation": "Yung RL, Richardson BC. Cytarabine therapy for refractory cutaneous lupus. Arthritis Rheum. 1995 Sep;38(9):1341-3. No abstract available."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004643"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Michigan", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "February 1995", 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1999"
    }, 
    "geocoordinates": {}
}